Bullous pemphigoid (BP), which has no FDA-approved targeted therapies, leads to reddening of the skin and the formation of ...

Pemphigus is an autoimmune bullous disease, in which autoantibodies react with the cell–cell adhesion structures, desmosomes, causing blisters and erosions on the oral mucosa and skin.

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Shortly after we made a diagnosis of bullous pemphigoid in this minipig, we found that a second minipig in the colony had similar, but less severe, lesions. Again, we did not administer ...

—This study tested the hypothesis that pemphigus is associated with MS, dementia, and related disorders. Why? Bullous pemphigoid, with a similar pathogenesis, is associated with some neurologic ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

Our AMBD clinic specializes in the diagnosis and comprehensive management of patients with all of the subtypes of bullous disorders including pemphigus, pemphigoid, dermatitis herpetiformis, linear ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...